Inter Pharma Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Trinnawat Thanitnithiphan

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.3yrs
Eigendom CEO	31.2%
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

CEO

Trinnawat Thanitnithiphan

4.3yrs

Tenure

Dr. Trinnawat Thanitnithiphanm is the Independent Director at P.S.P. Specialties Public Company Limited since 2023. He formally known as Songwut Sakchalathorn serves as Director at Interpharma Public Compa...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Trinnawat Thanitnithiphan	CEO & Director	no data	geen gegevens	31.2% THB 679.9m
Chatkaew Krudkosol	Acting CFO & Acting Director of Accounting	1.4yrs	geen gegevens	geen gegevens
Napaporn Dechakarat	Director of Operations & Director	no data	geen gegevens	geen gegevens
Apimon Posri	Human Resources Director & Director	4.3yrs	geen gegevens	geen gegevens
Chompunuch Meevang	Company Secretary	3yrs	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van IP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Trinnawat Thanitnithiphan	CEO & Director	4.3yrs	geen gegevens	31.2% THB 679.9m
Napaporn Dechakarat	Director of Operations & Director	4.3yrs	geen gegevens	geen gegevens
Apimon Posri	Human Resources Director & Director	2.3yrs	geen gegevens	geen gegevens
Udom Kachintorn	Independent Chairman of the Board	4.9yrs	฿608.82k	geen gegevens
Sansanee Chaiyaroj	Independent Director	4.3yrs	฿533.82k	geen gegevens
Kamtorn Sila-On	Independent Director	3.8yrs	฿563.82k	geen gegevens
Pao Sriprasertsuk	Independent Director	3yrs	฿508.82k	geen gegevens
Nat Ativitavas	Director	2.3yrs	฿364.71k	geen gegevens
Yuttana Suwannachot	Director	1.8yrs	฿290.00k	geen gegevens

3.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van IP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Inter Pharma Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Inter Pharma Public Company Limited Announces CFO Changes

Inter Pharma Public Company Limited Announces Resignation of Terdkiat Prommool as Director

Less than half of directors are independent

Inter Pharma Public Company Limited Approves Election of Directors

Inter Pharma Public Company Limited Announces Chief Financial Officer Changes

Recent updates

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ฿0.006 (vs ฿0.019 in 2Q 2023)

Investor sentiment deteriorates as stock falls 26%

New minor risk - Share price stability

First quarter 2024 earnings released: EPS: ฿0.042 (vs ฿0.066 in 1Q 2023)

Investor sentiment deteriorates as stock falls 40%

Inter Pharma Public Company Limited Approves Dividend for the Year 2023, Payable on May 24, 2024

Now 20% overvalued

Dividend reduced to ฿0.035

Full year 2023 earnings: EPS and revenues miss analyst expectations

Inter Pharma Public Company Limited Proposes Dividend for the Year 2023, Payable on May 24, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: ฿0.037 (vs ฿0.09 in 3Q 2022)

New minor risk - Market cap size

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings released: EPS: ฿0.03 (vs ฿0.10 in 2Q 2022)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 9.7% to ฿18.10

Investor sentiment deteriorates as stock falls 25%

Inter Pharma Public Company Limited Announces CFO Changes

Investor sentiment deteriorates as stock falls 22%

First quarter 2023 earnings released: EPS: ฿0.11 (vs ฿0.10 in 1Q 2022)

Upcoming dividend of ฿0.18 per share at 1.6% yield

Price target decreased by 13% to ฿18.65

Inter Pharma Public Company Limited Announces Resignation of Terdkiat Prommool as Director

Consensus forecasts updated

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: ฿0.10 (vs ฿0.086 in 2Q 2021)

Inter Pharma Public Company Limited announced that it has received THB 1.04314 billion in funding from Innobic LL Holding Company Limited

Inter Pharma Public Company Limited Approves Election of Directors

Inter Pharma Public Company Limited Announces Chief Financial Officer Changes

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to ฿26.00

High number of new and inexperienced directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Inter Pharma Public Company Limited Proposes Omission of Dividend Payment for 2021

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2021 earnings released: EPS ฿0.088 (vs ฿0.064 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ฿0.086 (vs ฿0.059 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.091 (vs ฿0.048 in 1Q 2020)

Inter Pharma Public Company Limited Approves Cash Dividends for 2020, Payable on May 18, 2020

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS ฿0.26 (vs ฿0.28 in FY 2019)

Inter Pharma Public Company Limited, Annual General Meeting, Apr 26, 2021

Inter Pharma Public Company Limited (SET:IP) entered into an agreement to acquire Certain Assets of Teva Pharma (Thailand) Co., Ltd. from Teva Pharma (Thailand) Co., Ltd. for THB 160 million.

Investor sentiment improved over the past week

Inter Pharma Public Company Replaces Amornsakdi Ketcharoon with Kamtorn Sila-On as an Independent Director, Audit Committee, Chairman of the Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee, Effective February 8, 2021

New 90-day high: ฿19.70

Independent Director has left the company

Inter Pharma Public Company Limited Notifies the Resignation of Mr. Amornsakdi Ketcharoon from Independent Director, Audit Committee, Chairman of the Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee ,Effective from January 31, 2021

Investor sentiment improved over the past week

New 90-day high: ฿14.00

New 90-day high: ฿13.60

Third quarter 2020 earnings released: EPS ฿0.09

Interpharma Public Company Limited Announces Director Changes

New 90-day high - ฿13.40

Earnings released

New 90-day high - ฿11.70

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur